OXLUMO Drug Patent Profile
✉ Email this page to a colleague
When do Oxlumo patents expire, and when can generic versions of Oxlumo launch?
Oxlumo is a drug marketed by Alnylam Pharms Inc and is included in one NDA. There are fourteen patents protecting this drug.
This drug has one hundred and seventy-four patent family members in forty-two countries.
The generic ingredient in OXLUMO is lumasiran sodium. One supplier is listed for this compound. Additional details are available on the lumasiran sodium profile page.
DrugPatentWatch® Generic Entry Outlook for Oxlumo
Oxlumo was eligible for patent challenges on November 23, 2024.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 9, 2035. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OXLUMO?
- What are the global sales for OXLUMO?
- What is Average Wholesale Price for OXLUMO?
Summary for OXLUMO
| International Patents: | 174 |
| US Patents: | 14 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 2 |
| Drug Prices: | Drug price information for OXLUMO |
| What excipients (inactive ingredients) are in OXLUMO? | OXLUMO excipients list |
| DailyMed Link: | OXLUMO at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for OXLUMO
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for OXLUMO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Alnylam Pharmaceuticals | Phase 2 |
| Alnylam Pharmaceuticals | Phase 3 |
US Patents and Regulatory Information for OXLUMO
OXLUMO is protected by fourteen US patents and four FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of OXLUMO is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting OXLUMO
Glycoconjugates of RNA interference agents
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)
Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)
Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)
Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)
Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)
Modified double-stranded RNA agents
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)
Modified double-stranded RNA agents
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)
Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)
Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)
Modified double-stranded RNA agents
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)
Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Carbohydrate conjugates as delivery agents for oligonucleotides
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)
Carbohydrate conjugates as delivery agents for oligonucleotides
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)
Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting OXLUMO
TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1) TO LOWER URINARY OXALATE LEVELS IN PEDIATRIC AND ADULT PATIENTS
Exclusivity Expiration: ⤷ Sign Up
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1) TO LOWER PLASMA OXALATE LEVELS IN PEDIATRIC AND ADULT PATIENTS
Exclusivity Expiration: ⤷ Sign Up
EXPANDED INDICATION TO INCLUDE LOWERING OF PLASMA OXALATE LEVELS IN ADULT AND PEDIATRIC PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1)
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for OXLUMO
When does loss-of-exclusivity occur for OXLUMO?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 2257
Patent: COMPOSICIONES Y MÉTODOS PARA LA INHIBICIÓN DE LA EXPRESIÓN GÉNICA DE HAO1 (HIDROXIÁCIDO OXIDASA 1 (GLICOLATO OXIDASA))
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 15330726
Patent: Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Estimated Expiration: ⤷ Sign Up
Patent: 21269372
Patent: Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2017006469
Patent: composições e métodos para inibição de expressão do gene hao1 (hidroxiácido oxidase 1 (glicolato oxidase))
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 63843
Patent: COMPOSITIONS ET METHODES D'INHIBITION DE L'EXPRESSION GENIQUE D'HAO1 (HYDROXYACIDE OXYDASE 1 (GLYCOLATE OXYDASE)) (COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION)
Estimated Expiration: ⤷ Sign Up
Patent: 87050
Patent: COMPOSITIONS ET METHODES D'INHIBITION DE L'EXPRESSION GENIQUE D'HAO1 (HYDROXYACIDE OXYDASE 1 (GLYCOLATE OXYDASE)) (COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION)
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 17000872
Patent: Composiciones y métodos para la inhibición de la expresión génica de hao1 (hidroxiácido oxidasa 1 (glicolato oxidasa)
Estimated Expiration: ⤷ Sign Up
China
Patent: 8064154
Patent: 用于抑制HAO1(羟酸氧化酶1(乙醇酸盐氧化酶))基因表达的组合物及方法 (Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression)
Estimated Expiration: ⤷ Sign Up
Patent: 3599389
Patent: 用于抑制HAO1(羟酸氧化酶1(乙醇酸盐氧化酶))基因表达的组合物及方法 (Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression)
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 17004728
Patent: Composiciones y métodos para inhibir la expresión del gen hao1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa)
Estimated Expiration: ⤷ Sign Up
Costa Rica
Patent: 170190
Patent: COMPOSICIONES Y MÉTODOS PARA INHIBIR LA EXPRESIÓN DEL GEN HA01 (HIDROXIÁCIDO-OXIDASA 1(GLICOLATO-OXIDASA))
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0211971
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 25364
Estimated Expiration: ⤷ Sign Up
Patent: 22008
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 04015
Estimated Expiration: ⤷ Sign Up
Dominican Republic
Patent: 017000094
Patent: COMPOSICIONES Y MÉTODOS PARA INHIBIR LA EXPRESIÓN DEL GEN HAO1 (HIDROXIÁCIDO-OXIDASA 1 (GLICOLATO-OXIDASA))
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 17028310
Patent: Composiciones y métodos para inhibir la expresión del gen HAO1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa))
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 7115
Patent: КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ ГЕНА HAO1 (ОКСИДАЗЫ 1 ГИДРОКСИКИСЛОТ (ГЛИКОЛАТ-ОКСИДАЗЫ)) (COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION)
Estimated Expiration: ⤷ Sign Up
Patent: 1790789
Patent: КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ ГЕНА HAO1 (ОКСИДАЗЫ 1 ГИДРОКСИКИСЛОТ (ГЛИКОЛАТ-ОКСИДАЗЫ))
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 04015
Patent: COMPOSITIONS ET MÉTHODES D'INHIBITION DE L'EXPRESSION GÉNIQUE D'HAO1 (HYDROXYACIDE OXYDASE 1 (GLYCOLATE OXYDASE)) (COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION)
Estimated Expiration: ⤷ Sign Up
Patent: 39809
Patent: COMPOSITIONS ET MÉTHODES D'INHIBITION DE L'EXPRESSION GÉNIQUE D'HAO1 (HYDROXYACIDE OXYDASE 1 (GLYCOLATE OXYDASE)) (COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 57327
Estimated Expiration: ⤷ Sign Up
Patent: 200011
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 1276
Patent: תכשירים ושיטות לעיכוב ביטוי גני של hao1 (הידרוקסיחומצה אוקסידאז 1 (גליקולאט אוקסידאז)) (Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression)
Estimated Expiration: ⤷ Sign Up
Patent: 3229
Patent: תכשירים ושיטות לעיכוב ביטוי גני של hao1 (הידרוקסיחומצה אוקסידאז 1 (גליקולאט אוקסידאז)) (Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression)
Estimated Expiration: ⤷ Sign Up
Patent: 0466
Patent: תכשירים ושיטות לעיכוב ביטוי גני של hao1 (הידרוקסיחומצה אוקסידאז 1 (גליקולאט אוקסידאז)) (Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 36988
Estimated Expiration: ⤷ Sign Up
Patent: 04212
Estimated Expiration: ⤷ Sign Up
Patent: 17532038
Patent: ＨＡＯ１（ヒドロキシ酸オキシダーゼ１（グリコール酸オキシダーゼ））遺伝子の発現の阻害のための組成物および方法
Estimated Expiration: ⤷ Sign Up
Patent: 21019609
Patent: ＨＡＯ１（ヒドロキシ酸オキシダーゼ１（グリコール酸オキシダーゼ））遺伝子の発現の阻害のための組成物および方法 (COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION)
Estimated Expiration: ⤷ Sign Up
Patent: 24037855
Patent: ＨＡＯ１（ヒドロキシ酸オキシダーゼ１（グリコール酸オキシダーゼ））遺伝子の発現の阻害のための組成物および方法 (COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXY ACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION)
Estimated Expiration: ⤷ Sign Up
Jordan
Patent: 0200115
Patent: تركيبات وطرق لتثبيط التعبير الجيني عن HAO1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) (Compositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression)
Estimated Expiration: ⤷ Sign Up
Patent: 58
Patent: تركيبات وطرق لتثبيط التعبير الجيني عن HAO1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) (Compositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression)
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 2022004
Estimated Expiration: ⤷ Sign Up
Patent: 04015
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 2926
Patent: COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 17004634
Patent: COMPOSICIONES Y METODOS PARA INHIBIR LA EXPRESION DEL GEN DE HIDROXIACIDO-OXIDASA 1 (GLICOLATO-OXIDASA) (HAO1). (COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION.)
Estimated Expiration: ⤷ Sign Up
Patent: 21005224
Patent: COMPOSICIONES Y METODOS PARA INHIBIR LA EXPRESION DEL GEN DE HIDROXIACIDO-OXIDASA 1 (GLICOLATO-OXIDASA) (HAO1). (COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION.)
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 049
Patent: COMPOSITIONS ET MÉTHODES D'INHIBITION DE L'EXPRESSION GÉNIQUE D'HAO1 (HYDROXYACIDE OXYDASE 1 (GLYCOLATE OXYDASE))
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 0404
Patent: Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Estimated Expiration: ⤷ Sign Up
Norway
Patent: 22009
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 171763
Patent: COMPOSICIONES Y METODOS PARA INHIBIR LA EXPRESION DEL GEN HAO1 (HIDROXIACIDO-OXIDASA 1 (GLICOLATO-OXIDASA))
Estimated Expiration: ⤷ Sign Up
Philippines
Patent: 017500669
Patent: COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 04015
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 04015
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 854
Patent: KOMPOZICIJE I POSTUPCI ZA INHIBICIJU EKSPRESIJE GENA HAO1 (OKSIDAZA 1 HIDROKSILNE KISELINE (GLIKOLAT OKSIDAZA)) (COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION)
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 201913756Q
Patent: COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION
Estimated Expiration: ⤷ Sign Up
Patent: 201702836P
Patent: COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 04015
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1702071
Patent: COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 2558604
Estimated Expiration: ⤷ Sign Up
Patent: 170083042
Patent: HAO1 유전자 발현의 억제를 위한 조성물 및 방법 (HAO1 1 COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1HYDROXYACID OXIDASE 1GLYCOLATE OXIDASE GENE EXPRESSION)
Estimated Expiration: ⤷ Sign Up
Patent: 230113654
Patent: HAO1유전자 발현 억제용 조성물 및 방법 (HAO1 1 COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1HYDROXYACID OXIDASE 1GLYCOLATE OXIDASE GENE EXPRESSION)
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 05889
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 55351
Estimated Expiration: ⤷ Sign Up
Patent: 1619382
Patent: Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Estimated Expiration: ⤷ Sign Up
Patent: 2223090
Patent: Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Estimated Expiration: ⤷ Sign Up
Patent: 2342749
Patent: Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Estimated Expiration: ⤷ Sign Up
Tunisia
Patent: 17000125
Patent: COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 6266
Patent: ДВОНИТКОВИЙ ЗАСІБ ДЛЯ RNAi, ЗДАТНИЙ ІНГІБУВАТИ ЕКСПРЕСІЮ HAO1 (ОКСИДАЗИ 1 ГІДРОКСИКИСЛОТ (ГЛІКОЛАТОКСИДАЗИ)) В КЛІТИНІ (COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION)
Estimated Expiration: ⤷ Sign Up
Uruguay
Patent: 357
Patent: COMPOSICIONES Y MÉTODOS PARA LA INHIBICIÓN DE LA EXPRESIÓN GÉNICA DE HAO1 (HIDROXIÁCIDO OXIDASA 1 (GLICOLATO OXIDASA))
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering OXLUMO around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Serbia | 62854 | KOMPOZICIJE I POSTUPCI ZA INHIBICIJU EKSPRESIJE GENA HAO1 (OKSIDAZA 1 HIDROKSILNE KISELINE (GLIKOLAT OKSIDAZA)) (COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION) | ⤷ Sign Up |
| Canada | 3043911 | LIPIDES DE CIBLAGE (TARGETING LIPIDS) | ⤷ Sign Up |
| Japan | 2015025007 | 標的化脂質 (TARGETED LIPID) | ⤷ Sign Up |
| Eurasian Patent Organization | 037115 | КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ ГЕНА HAO1 (ОКСИДАЗЫ 1 ГИДРОКСИКИСЛОТ (ГЛИКОЛАТ-ОКСИДАЗЫ)) (COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for OXLUMO
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3204015 | C20220010 00364 | Estonia | ⤷ Sign Up | PRODUCT NAME: LUMASIRAAN;REG NO/DATE: EU/1/20/1496 23.11.2020 |
| 3581654 | 122021000053 | Germany | ⤷ Sign Up | PRODUCT NAME: LUMASIRAN; REGISTRATION NO/DATE: EU/1/20/1496 20201119 |
| 3204015 | CR 2022 00011 | Denmark | ⤷ Sign Up | PRODUCT NAME: LUMASIRAN EVENTUELT I FORM AF ET SALT; REG. NO/DATE: EU/1/20/1496 20201123 |
| 3581654 | PA2021008 | Lithuania | ⤷ Sign Up | PRODUCT NAME: LUMASIRANAS; REGISTRATION NO/DATE: EU/1/20/1496 20201119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
